Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge assists Vostok New Ventures Ltd in connection with an investment in Voi
Mandate

Vinge assists Vostok New Ventures Ltd in connection with an investment in Voi

November 27, 2018 Capital Markets and Public M&A

Vinge has assisted Vostok New Ventures Ltd (“Vostok”) in connection with an investment by a number of investors in Voi Technology AB, a company that provides an electric scooter sharing service.

Vostok is an investment and asset management company that invests in both private equity and public equity markets with a special focus on online marketplaces and businesses with strong network effects. The Swedish depository receipts of Vostok are listed on Nasdaq Stockholm, Mid Cap segment.

Vinge’s team consisted of Jesper Schönbeck, Joel Wahlberg, Samra Baytar and Stephanie Stiernstedt.
 

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024